Ocedurenone

Ocedurenone
Clinical data
Other namesKBP-5074
Legal status
Legal status
  • Investigational
Identifiers
  • 4-[(3S,3aR)-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H30ClN5O2
Molar mass504.03 g·mol−1

Ocedurenone, formerly known as KBP-5074, is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments. In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for up to USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.